

EVALUATING EXPOSURE-RESPONSE RELATIONSHIP IN 1,3-BUTADIENE AND LEUKEMIA STUDIES

EVANGELIA E. ANTONIOU¹ and CHRIS KIRMAN²

¹ Epicurus-Reviews, MetaAnalyses.com, Bilzen, Belgium

² SciPinion, Bozeman, Montana, USA

Abstract

Objectives: 1,3-Butadiene (BD) exposure's link to leukemia is under regulatory scrutiny. The assessment methods for BD exposure risks have evolved from early animal and limited human studies to advanced exposure-response modelling with comprehensive quantitative data. The objective of this study is to explore the nuances of exposure-response modelling, investigating how various statistical methods have influenced the quantification of exposure-response relationships. **Material and Methods:** Although this study was not conducted as a formal systematic review, a search was performed in Medline/Pubmed to identify all human studies on leukemia risk assessment for BD exposure. This search included articles written in English. The electronic search spanned from inception of records until July 23, 2023, using the search term: "butadiene AND (leukaemia OR leukemia OR myeloid OR lymphoid)" and was restricted to human species. Focusing on the synthetic styrene-butadiene rubber (SBR) industry cohort study conducted by the University of Alabama at Birmingham, USA, this review evaluates various statistical models and factors influencing exposure-response modelling. **Results:** Peak exposures to BD may be more influential in the dose-response relationship than cumulative or long-term exposure. The authors recommend utilizing β -coefficients derived from the latest SBR study update, employing Cox proportional hazard modelling, non-lagged and non-transformed cumulative BD exposure, and adjusting for age and peak BD exposure. The study reveals that statistical model selection has a limited impact on the calculated dose-response effects. The significant variation in estimated cancer mortality values arises from additional assumptions needed for metrics like the excess leukemia risk or the occupational BD effective concentration. **Conclusions:** In conclusion, this study provides insights into exposure-response modelling for BD exposure and leukemia mortality, highlighting the importance of peak exposures. The recommended statistical approach offers a reliable basis for regulatory risk assessment and public health population metrics. *Int J Occup Med Environ Health* 2024;37(3)

Key words:

risk assessment, leukemia, exposure-response modelling, occupational cohort study, regulatory toxicology, 3-butadiene

INTRODUCTION

Over the years, investigations of the association between 1,3-butadiene (BD) exposure and the risk on leukemia and other cancers have drawn significant attention from various regulatory bodies [1–3]. The methodology for evaluating the risk of such health outcomes of BD exposure has undergone substantial development in recent decades. Initially, these models were based exclusively on animal studies or human studies with limited and generally qualitative exposure information [4].

In more recent years, progress in exposure-response modelling and the availability of comprehensive quantitative exposure data in humans has facilitated the formulation of risk assessments that account for potential health impacts on human populations exposed to BD. Four occupational cohort studies, conducted in the USA, have reported on the association between BD exposure and cancer mortality risk. Nevertheless, all regulatory bodies have based their cancer mortality risk assessment conclusions on the same occupational cohort study on workers

Funding: this study was supported by the European Chemical Industry Council, sector group LOSG, Brussels, Belgium.

Received: January 27, 2024. Accepted: May 15, 2024.

Corresponding author: Evangelia E. Antoniou, Epicurus-Reviews, MetaAnalyses.com, Heesstraat 80, Bilzen, Belgium (e-mail: e.antoniou@epicurus-reviews.com).

exposed to BD as conducted by the University of Alabama at Birmingham (UAB), USA, in their epidemiological study of North American workers in the synthetic styrene-butadiene rubber (SBR) industry (hereafter called the SBR study). Several studies, which are described and cited below in the study selection, have been conducted using the SBR cohort data. The other 3 cohorts [4–8] have not been used often mainly due to lack of historical industrial hygiene sampling data [4–6,8], no available quantitative exposure data [4–6], smaller cohort sizes [4–6] and lack of long-term follow-up [7,8]. The SBR study, however, has been frequently updated throughout the years adding to the robustness of the dataset.

The SBR study data has been used multiple times by various researchers using diverse statistical approaches to quantify the dose-response relationship between BD exposure and leukemia mortality. The objective of this article is to explore the nuances of exposure-response modelling, with a particular focus on assessing how various statistical methods have influenced the quantification of exposure-response relationships differently.

MATERIAL AND METHODS

Sources

Although this analysis was not conducted as a formal systematic review, a search was performed in Medline/Pubmed to identify all human studies with an outcome on leukemia mortality and BD exposure. This search included articles written in English. The electronic search spanned from inception of records until July 23, 2023, using the search term: “butadiene AND (leukaemia OR leukemia OR myeloid OR lymphoid)” and was restricted to human species. Only occupational cohort studies were selected. Conversely, case series, cross-sectional studies, reviews, and animal studies were excluded. In a second phase, the authors further excluded studies that provided no quantitative exposure-response metrics, no leukemia mortality endpoint,

and cohort studies in which no Cox regression survival analysis was used.

Methods for characterizing the exposure-response relationship for BD and leukemia from epidemiology data have included Poisson and Cox proportional hazards regression. Unlike Poisson regression, Cox regression optimally controls for age by considering each specific age rather than age categories. This also allows cumulative exposure (e.g., BD ppm-years) to be treated as a continuous variable instead of necessitating categorization. Since the SBR study adopted Cox proportional hazard models in its most recent updates, particularly post-1998, this study explores data from these hazard models derived from the years 1998 and 2009 of the SBR follow up.

Data collection

The authors examined the statistical analysis results for each publication, specifically focusing on the regression terms related to BD's cancer potency, which is expressed through the metric of cancer slope factor or slope of the exposure-response relationship (i.e., β -coefficients). These analyses involved regressing cumulative BD (ppm-years) exposure against the time to die from leukemia. Cumulative exposures emphasize both exposure magnitude and duration. While alternative exposure metrics have been considered, no straightforward alternative models have emerged thus far. The impact of each statistical model was evaluated by:

- the cohort size and number of patients,
- whether lag years were included in the analysis,
- the leukemia type(s) assessed,
- if other BD exposure variables were included in the model,
- whether the exposure variables were transformed,
- which non-exposure covariate variables were factored into the regression model.

For each regression analyses, the authors noted the resulting β -coefficients of the BD exposure variable

along with their standard errors (SEs). Unless otherwise specified, these β -coefficients represent an increased leukemia mortality risk per cumulative BD ppm-year after Cox regression analyses. Where relevant, the goodness-of-fit of the models (as expressed by the Akaike information criterion (AIC) [9] or the $-2 \log$ likelihood ($-2LL$) of each statistical model) was also assessed.

Presentation of results

After a brief overview of the SBR study, the authors will summarize the different statistical models used and their impact on the exposure-response relationship. This is achieved by discussing 6 crucial components in the exposure-response modelling procedure:

- the influence of time (with a focus on all-type leukemia),
- the selection of the exposure variable (concentrating on cumulative BD exposure and its transformations),
- the potential role of lag years (that is, whether or not recent exposures should be included),
- the influence of non-exposure and exposure covariates (with emphasis on the cumulative number of BD high-intensity tasks),
- whether all-type leukemia should be the preferred endpoint in BD exposure-dose modelling.

RESULTS

Study selection

The initial database search yielded a total of 187 publications. Among these studies, 28 publications were further screened for eligibility in the review. From this subset, 13 publications [10–22] with primary data based on the SBR updates after 1998 were considered for inclusion in the review. Ultimately, eight publications, which presented exposure-response data utilizing Cox proportional hazard model data derived from the SBR study of 1998 and 2009 were included in this impact analysis [10–17].

SBR study description

Among the first studies initially conducted within SBR production, one study consisted of 2756 workers from a 2-plant complex in Texas, USA [23] and a second group of studies included about 13 000 workers from 8 facilities across the USA and Canada studied by researchers at John Hopkins University (JHU), USA [24–27]. Later, a team of researchers from the UAB expanded on the number of workers, by investigating the same 2-plant complex in Texas plus 7 of the 8 plants studied by the JHU extending the workers' follow up until 1991 with 15 649 workers [28]. The UAB research group continued to update the cohort's follow up, enhancing their assessment of BD exposures and addressing potential confounding co-exposures in their analyses [29–31]. Subsequently, the refinement of exposure assessments was coupled with an expansion in the cohort's size including follow up extensions until 1998 [13–20], 2002 [21] and the latest follow up update extending to 2009 [10–12,22]. In the 1998 update the SBR study comprised of 17 924 workers measuring 120 leukemia decedents. Starting from 2002, 4861 female workers were added to the cohort [21]. In its most recent update (2009), the SBR study comprises 22 785 (17 924 men and 4861 women) cohort members with a follow up of 65 years and 132 leukemia decedents (Table 1).

The exposure-response effect of cumulative BD exposure in different follow-up rounds

Two statistical models were tested across different follow-up periods of the SBR study (Table 2). These were Cox regression models in which the relationship between cumulative BD exposure (in ppm-years) was related to the mortality risk of leukemia. One model adjusted only for age and the other model adjusted for age and the cumulative number of BD high intensity tasks (HITs), i.e., tasks with exposures ≥ 100 ppm BD, also called peak exposures. When correcting for age only, the increase leukemia mortality risk per ppm-year has remained remark-

Table 1. Occupational worker studies on 1,3-butadiene exposure in 1943–1991 in the styrene-butadiene rubber (SBR) industry in USA and Canada

Reference	Plants [n]	Period		Country	Workers		Deaths [n]
		exposure	follow-up		gender	n	
Meinhardt et al. 1982 [23]	2	1943–1976	1943–1976	USA (Texas)	male	2756	332
Matanoski et al. 1987 [24], Matanoski et al. 1990 [25], Matanoski et al. 1997 [26], Santos-Burgoa et al. 1992 [27]	8	1942–1982	1943–1982	USA and Canada	male	13 422	2441
Delzell et al. 1996 [28]	8	1944–1991	1943–1992	USA and Canada	male	15 649	3976
Sielken and Valdez-Flores 2008 [13], Sielken and Valdez- Flores 2013 [14], Sielken and Valdez-Flores 2011 [15], Sielken and Valdez-Flores 2015 [16], Cheng et al. 2007 [17], Sielken et al. 2007 [18], Sathiakumar et al. 2005 [19], Graff et al. 2005 [20]	8	1944–1991	1944–1998	USA and Canada	male	17 924	6237
Sathiakumar et al. 2009 [21]	8	1944–1991	1944–2002	USA and Canada	female	4861	1198
Sathiakumar et al. 2021, [10], Sathiakumar et al. 2015 [11], Valdez-Flores 2022 [12], Sathiakumar et al. 2019 [22]	8	1944–1991	1944–2009	USA and Canada	male and female	22 785	10 617

Table 2. Beta-coefficients of an increased leukemia mortality risk per cumulative 1,3-butadiene (BD) ppm-year based on Cox regression analyses, adjusted for age and age and BD high intensity tasks (HITs) in different styrene-butadiene rubber publications

Reference	Follow-up	β	SE
Model 1: adjustment for age			
Cheng et al. 2007 [17]	1998	0.00029	0.00011
Sielken and Valdez-Flores 2008 [13]	1998	0.00029	0.00010
Sielken and Valdez-Flores 2011 [15]	1998	0.00029	0.00010
Sathiakumar et al. 2015 [11]	2009	0.00026	0.00009
Sielken and Valdez-Flores 2015 [16]	2009	0.00029	0.00010
Valdez-Flores et al. 2022 [12]	2009	0.00028	0.00009
Model 2: adjustment for age and BD HITs			
Sielken and Valdez-Flores 2008 [13]	1998	0.00022	0.00013
Sielken and Valdez-Flores 2011 [15]	1998	0.00020	0.00013
Sielken and Valdez-Flores 2015 [16]	1998	0.00020	0.00013
Valdez-Flores et al. 2022 [12]	2009	0.00013	0.00011

ably consistent over time. However, with the additional adjustment for peak exposures, a reduction of >50% in leukemia mortality risk per ppm-year for cumulative exposures was observed in the SBR dataset with the lon-

gest follow-up. Interestingly, in this latest dataset, this exposure-response relationship for cumulative exposures was also no longer statistically significant. The SEs estimates remained stable too, regardless of follow-up or covariate adjustment. This outcome highlights the importance of peak exposures versus chronic cumulative exposures and for considering adjustment for peak exposures in dose-response analyses of this kind.

Alternative transformations of BD exposure

Two studies [11,17] examined the influence of transforming cumulative BD exposure through logarithmic or square root conversions (Table 3). In both cases, the findings indicate that the model's fit remained relatively consistent, regardless of the specific type of transformation applied. Furthermore, Cheng et al. [17] also showed that the categorization of continuous BD exposure into deciles did not notably enhance the statistical fit, concluding that the untransformed BD variable in its full range and continuous form was preferable. This observation implies that for the use of untransformed cumulative exposure to BD in ppm-years is advisable, for the sake of model accuracy and ease of interpretation.

Table 3. Model fit of models on increased leukemia mortality risk per cumulative 1,3-butadiene (BD) ppm-year based on Cox regression analyses, adjusted for age, in different styrene-butadiene rubber publications

Transformation	Model fit
Cheng et al. 2007 [17] – follow-up 1998	
none	1384.12 (–2LL)
logarithmic	1378.77 (–2LL)
square root	1346.64 (–2LL)
Sathiakumar et al. 2015 [11] – follow-up 2009	
none	2007.44 (AIC)
logarithmic	1998.24 (AIC)
square root	1998.89 (AIC)

–2LL – –2 log likelihood (a lower value indicates a better model fit);

AIC – Akaike information criterion (a lower value indicates a better balance between model complexity and model fit).

Exposure may or may not be converted to square root or logarithmic scales.

Differences in outcome based on ceiling levels of BD exposure

Sielken and Valdez-Flores [14] investigated the effect of ceiling levels for cumulative BD ppm-years. A ceiling of e.g., ≤ 100 ppm-years means that any cumulative exposure that is >100 ppm-years is disregarded (Table 4). The β -coefficients in this study seem to get larger as the restriction becomes tighter. Although approached differently, this finding also suggests that peak exposure to BD may have a clearer dose-response association with leukemia mortality than long duration exposures of low intensity. However, the SEs increased and consequently the statistical significance for leukemia diminished when the modelling was restricted to person years with an accumulation of ≤ 300 , ≤ 200 or ≤ 100 cumulative BD ppm-years.

Impact of lagged exposures

Sielken and Valdez-Flores [13] presented a Cox regression model for the dose-response association between cumulative BD exposure (ppm-years) and leukemia mor-

Table 4. Beta-coefficients of an increased leukemia mortality risk per cumulative 1,3-butadiene (BD) ppm-year based on Cox regression analyses, adjusted for age [14]

BD exposure	β	SE
≤ 1338 ppm-years	0.00121	0.00036
≤ 1000 ppm-years	0.00145	0.00047
≤ 500 ppm-years	0.00296	0.00086
≤ 400 ppm-years	0.00283	0.00111
≤ 300 ppm-years	0.00305	0.00155
≤ 200 ppm-years	0.00089	0.00267
≤ 100 ppm-years	0.00224	0.00536

Table 5. Beta-coefficients of an increased leukemia mortality risk per cumulative 1,3-butadiene (BD) ppm-year by exposure lag time based on Cox regression analyses, adjusted for age and BD high intensity tasks (HITs) [13]

Lag time	β
5	0.00023
10	0.00023
15	0.00026
20	0.00027

tality, with adjustments for age and peak exposure across various lag years (Table 5). The cumulative BD exposure is lagged when both exposures that took place 40 years ago and the most recent exposures (such as those within the last 5 years, 10 years or 20 years) are not included in the analyses. The β -coefficient for these analyses, without taking lag years into account, was 0.00022 (Table 2). One would expect the β values to increase with increasing lag time, however, Table 5 shows that the modelling of lagged exposures did not influence this β -coefficient substantially and may therefore not be needed. Similarly, in the study by Valdez-Flores et al. [12] (that did not adjust for BD HITs) models with lagged BD ppm-years did not outperform the model with unlagged BD ppm-years at the 5% significance level.

Table 6. Beta-coefficients of an increased leukemia mortality risk per cumulative 1,3-butadiene (BD) ppm-year from Cox regression analyses, adjusted for age and other covariates, in different styrene-butadiene rubber publications

Non-exposure covariate adjustment in addition to age	β	SE
Sielken and Valdez-Flores 2008 [13] – follow-up 2009		
years since hire	0.00029	0.00011
plant	0.00026	0.00012
years since hire	0.00039	0.00012
plant	0.00029	0.00011
Sielken and Valdez-Flores 2011 [13] – follow-up 1998		
years since hire	0.00029	0.00010
race	0.00026	0.00012
plant	0.00039	0.00012
calendar year	0.00028	0.00010
Sathiakumar et al. 2015 [11] – follow-up 2009: race, plant	0.00029	0.00010
Sathiakumar et al. 2021 [10] – follow-up 2009: race, plant, sex, age at hire, year of hire, ever hourly status	0.00026	0.00010

Adjustment of non-exposure covariates

The SBR study included 6 non-exposure variables (i.e., age, years since hire, calendar year, sex, race, and plant) that can be tested for their potential confounding influence on the β -coefficients. Valdez-Flores et al. [12] examined whether the inclusion of these additional covariates improves the model fit after adjustment for age and BD HITs but did not observe a statistically significant improvement at a 1% significance level. The effects on the β -coefficients due to residual confounding of other covariates after adjustment for only age can be found in Table 6. Comparison to the β -coefficients of Table 1 (adjustment for age only) shows that additional adjustment for non-exposure variables does not alter the effect estimates and thus may not be needed.

The SBR study had no information on the cigarette smoking habits of the workers, while it is likely that 50–80% of the workers may have smoked [32] and smoking itself is a source of non-occupational BD exposure [33]. Although leukemia has not been strongly linked to smoking [34,35], to the extent smoking remains as a possible independent risk factor for leukemia [36] the β -coefficients may be biased upwards if correction for smoking is not performed.

Leukemia as the best potential blood cancer endpoint

Leukemia is a broad term encompassing a group of blood cancers that can be classified into different subtypes based on various factors, including the type of blood cells affected (lymphoid or myeloid). Three studies presented Cox regression models that were adjusted for age and peak exposure to BD HITs across leukemia subtypes (Table 7). The findings indicate that the estimated exposure-response effects for chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML) and myeloid neoplasms in general are comparatively lower than those for all leukemia combined (Table 1). Therefore, leukemia appears to be the preferred endpoint for regulatory considerations due to its heightened sensitivity as an outcome as well as the larger number of cases available. That being said, the “all leukemias combined” category may not be the most biologically aligned endpoint given that the leukemia subtypes have unique histological features [37].

At present, the SBR study possesses information regarding leukemia mortality but lacks data on leukemia incidence. It would have been more advantageous to have

Table 7. Beta-coefficients of an increased leukemia mortality risk per cumulative 1,3-butadiene (BD) ppm-year after Cox regression analyses, adjusted for age and BD high intensity tasks (HITs) in different styrene-butadiene rubber publications with follow-up until 1998

Endpoint	β	SE
Sielken and Valdez-Flores 2008 [13]		
chronic lymphoid leukemia	0.00037	0.00015
chronic myeloid leukemia	-0.00013	0.00061
Sielken and Valdez-Flores [14] – myeloid neoplasms	-0.00008	0.00033
Sielken and Valdez-Flores [15] – myeloid neoplasms	-0.00008	0.00033

incidence data, as mortality is not solely determined by exposure but also, by the treatment choices accessible at any given point in time.

While bladder cancer is not a blood cancer, it has recently emerged as a heightened risk linked to BD exposure in the latest cohort update [12], with a comparable effect size to that of leukemia. This study estimated an increased mortality risk per ppm BD exposure per year to be 0.00028 for leukemia (Table 2) and 0.00031 for bladder cancer after both models were adjusted for age.

DISCUSSION

This impact analysis has provided an overview of the different statistical models that were employed in the SBR studies to estimate the exposure-response relationship between cumulative exposure to BD and leukemia mortality risk. The authors' conclusion is that the variation in calculated exposure-response effects (β -coefficients) across different regression models, papers and cohort updates is relatively modest.

The authors' recommendation to those who will use these β -coefficients as input for public health population metrics, such as the ELR or the occupational BD effective concentration (OEC) is as follows: use a β -coefficient that is based on the latest and largest update of the SBR study, is derived from Cox regression modelling for the dose-

Table 8. Recommendation for the selection of β -coefficients for public health population metrics on 1,3-butadiene (BD) exposure and leukemia mortality risk

Cohort	Latest and largest update of the styrene-butadiene rubber study
Statistical method	Cox regression
Primary exposure	cumulative BD exposure in ppm-years
Lagged exposure	no
Transformation of exposure	no
Covariates	age, BD high intensity tasks
Endpoint	leukemia all subtypes

response relationship between non-lagged and non-transformed cumulative BD exposure (ppm-years) and leukemia mortality, with adjustment for age and peak exposure to BD (Table 8). This model is parsimonious, provides easy interpretation, has a good model fit and is one of the models with the largest statistical power. Valdez-Flores et al. [12] provided such a β -coefficient [38], i.e., 0.000132 (Table 2).

Due to the relative stability of β -coefficients, the large variation found in estimated ELRs or OECs is likely attributed to the additional assumptions required for calculating these values [38–40]. These assumptions include life-table data like time and region-specific data on survival probabilities, mortality rates across age-ranges of the outcome of interest, the choice between assuming daily and lifelong exposure to BD (environmental exposure) or only daily exposure during ones' working life (occupational exposure) and the decision of whether to use the maximum likelihood estimate of the β -coefficient itself as an input and/or the upper limit of 95% confidence interval (CI) of the β -coefficient, as some regulatory bodies have done.

Given the same β -coefficient, the life-table data will vary depending on the age-distribution and general health care and specific cancer treatment options available at a specific time and place. As the treatment options for

leukemia are continuously improving [41], the likelihood to die from leukemia has decreased. Even if all else would have remained stable, this means that the mortality and thus the ELRs must have decreased over time as well.

This article highlights the crucial role of peak BD exposures in the modelling process. Here, the authors propose the hypothesis that peak exposure may be more important than long-term and cumulative exposure to BD. This is supported by the following observations: The studies by Sielken and Valdez-Flores [13,15,16] and Valdez-Flores et al. [12] found that the cumulative number of BD HITs is a more important predictor of leukemia mortality than cumulative BD ppm-years. Their statistical models focused on the relationship of leukemia mortality and BD ppm-years, while adjusting for BD HITs, because the general population is not expected to be exposed to BD peaks (Table 2). Sielken and Valdez-Flores [14] showed that restricting to person years with ≤ 300 , ≤ 200 or ≤ 100 cumulative BD ppm-years, a low-exposure risk vs. cumulative BD ppm-years was observed (Table 4). Furthermore, Valdez-Flores et al. [12] found that the value of the β -coefficient for cumulative BD exposure more than halved after adjusting for BD HITs. Similarly, Cheng et al. [17] showed that all leukemia decedents in the SBR study exposed to BD had some peak exposures to BD, while no leukemia mortalities at all were found among exposed workers without peak exposures. Cheng et al. [17] also found a positive exposure-response relationship between BD HITs alone and leukemia mortality risk. Given the apparent importance of peak exposures, future studies might consider modelling this variable independently as a predictor in the occupational settings, instead of relying solely on cumulative BD ppm-years.

CONCLUSIONS

This review offers evidence to endorse the utilization of the latest SBR study update. This study boasts a large cohort, longitudinal exposure quantification of 47 years,

inclusion of both genders and a 65-year follow-up period covering over 50% of the cohort. Thus, it has the highest statistical power of available cohort studies to estimate potential effects of BD exposure. By acquiring and utilizing data from such high-quality human study available, there is no need for exposure-response extrapolations from animal studies for cancer endpoints.

The recommended approach involves employing the β -coefficient derived from Cox proportional hazard modelling for the relationship between non-lagged and non-transformed cumulative BD exposure and leukemia mortality, with adjustment for age and peak exposure to BD.

Conflict of interests

The sponsors had no role in the design, execution, interpretation, or writing of the study. The opinions expressed herein are those of the authors, not of their employers or funders.

Author contributions

Research concept: Evangelia E. Antoniou, Chris Kirman

Research methodology: Evangelia E. Antoniou, Chris Kirman

Interpretation of results: Evangelia E. Antoniou, Chris Kirman

References: Evangelia E. Antoniou

REFERENCES

1. U.S. EPA. Health Assessment of 1,3-Butadiene. U.S. Environmental Protection Agency. Office of Research and Development, National Center for Environmental Assessment; 2002.
2. Dutch Expert Committee for Occupational Safety Report (DECOS) No. 2013/08., Health Council of the Netherlands, Health Council of the Netherlands. 1,3-Butadiene; Health-based calculated occupational cancer risk values. 2013.
3. Texas Commission on Environmental Quality (TCEQ). Development Support Document: 1,3-butadiene. Final, August 7, 2008, Accessible 2013, 24-Hour Reference Value added, September 14, 2015. 2008.

4. Divine BJ, Hartman CM. A cohort mortality study among workers at a 1,3-butadiene facility. *Chem Biol Interact.* 2001 Jun;135–136:535–53.
5. Divine BJ, Hartman CM. Mortality update of butadiene production workers. *Toxicology.* 1996 Oct;113(1–3):169–81.
6. Divine BJ. An update on mortality among workers at a 1,3-butadiene facility--preliminary results. *Environ Health Perspect.* 1990 Jun;86:119–28.
7. Ward EM, Fajen JM, Ruder AM, Rinsky RA, Halperin WE, Fessler-Flesch CA. Mortality study of workers in 1,3-butadiene production units identified from a chemical workers cohort. *Environ Health Perspect.* 1995 Jun;103(6):598–603.
8. Tsai SP, Wendt JK, Ransdell JD. A mortality, morbidity, and hematology study of petrochemical employees potentially exposed to 1,3-butadiene monomer. *Chem Biol Interact.* 2001 Jun;135–136:555–67.
9. Bozdogan H. Model selection and Akaike's Information Criterion (AIC): The general theory and its analytical extensions. *Psychometrika.* 1987 Sep;52(3):345–70.
10. Sathiakumar N, Bolaji BE, Brill I, Chen L, Tipre M, Leader M, et al. 1,3-Butadiene, styrene and lymphohaematopoietic cancers among North American synthetic rubber polymer workers: exposure-response analyses. *Occup Environ Med.* 2021 Dec;78(12):859–68.
11. Sathiakumar N, Brill I, Leader M, Delzell E. 1,3-Butadiene, styrene and lymphohematopoietic cancer among male synthetic rubber industry workers – Preliminary exposure-response analyses. *Chem Biol Interact.* 2015 Nov;241:40–9.
12. Valdez-Flores C, Erraguntla N, Budinsky R, Cagen S, Kirman CR. An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene. *Chem Biol Interact.* 2022 Oct;366:110077.
13. Sielken RL, Valdez-Flores C. Quantitative Risk Assessment of Exposures to Butadiene in European Union Occupational Settings Based on the University of Alabama at Birmingham Epidemiological Study: All Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myelogenous Leukemia. *Olefins Panel of the American Chemistry Council (ACC);* 2008.
14. Sielken RL, Valdez-Flores C. Quantitative risk assessment of exposures to butadiene in EU occupational settings based on the University of Alabama at Birmingham epidemiological study. *Regul Toxicol Pharmacol.* 2013 Mar;65(2):214–25.
15. Sielken RL, Valdez-Flores C. Butadiene cancer exposure-response modeling: Based on workers in the styrene-butadiene-rubber industry: Total leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia. *Regul Toxicol Pharmacol.* 2011 Aug;60(3):332–41.
16. Sielken RL, Valdez-Flores C. A comprehensive review of occupational and general population cancer risk: 1,3-Butadiene exposure-response modeling for all leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloid neoplasm and lymphoid neoplasm. *Chem Biol Interact.* 2015 Nov;241:50–8.
17. Cheng H, Sathiakumar N, Graff J, Matthews R, Delzell E. 1,3-Butadiene and leukemia among synthetic rubber industry workers: exposure-response relationships. *Chem Biol Interact.* 2007 Mar 20;166(1–3):15–24.
18. Sielken RL, Valdez-Flores C, Gargas ML, Kirman CR, Teta MJ, Delzell E. Cancer risk assessment for 1,3-butadiene: Dose-response modeling from an epidemiological perspective. *Chem Biol Interact.* 2007 Mar;166(1–3):140–9.
19. Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R, Delzell E. An updated study of mortality among North American synthetic rubber industry workers. *Occup Environ Med.* 2005 Dec;62(12):822–9.
20. Graff JJ, Sathiakumar N, Macaluso M, Maldonado G, Matthews R, Delzell E. Chemical Exposures in the Synthetic Rubber Industry and Lymphohematopoietic Cancer Mortality: *J Occup Environ Med.* 2005 Sep;47(9):916–32.

21. Sathiakumar N, Delzell E. A follow-up study of mortality among women in the North American synthetic rubber industry. *J Occup Environ Med.* 2009 Nov;51(11):1314–25.
22. Sathiakumar N, Tipre M, Leader M, Brill I, Delzell E. Mortality Among Men and Women in the North American Synthetic Rubber Industry, 1943 to 2009. *J Occup Environ Med.* 2019 Nov;61(11):887–97.
23. Meinhardt TJ, Lemen RA, Crandall MS, Young RJ. Environmental epidemiologic investigation of the styrene-butadiene rubber industry. Mortality patterns with discussion of the hematopoietic and lymphatic malignancies. *Scand J Work Environ Health.* 1982 Dec;8(4):250–9.
24. Matanoski GM, Schwartz L. Mortality of workers in styrene-butadiene polymer production. *J Occup Med Off Publ Ind Med Assoc.* 1987 Aug;29(8):675–80.
25. Matanoski GM, Santos-Burgoa C, Schwartz L. Mortality of a cohort of workers in the styrene-butadiene polymer manufacturing industry (1943–1982). *Environ Health Perspect.* 1990 Jun;86:107–17.
26. Matanoski G, Elliott E, Tao X, Francis M, Correa-Villaseñor A, Santos-Burgoa C. Lymphohematopoietic cancers and butadiene and styrene exposure in synthetic rubber manufacture. *Ann N Y Acad Sci.* 1997 Dec 26;837:157–69.
27. Santos-Burgoa C, Matanoski GM, Zeger S, Schwartz L. Lymphohematopoietic cancer in styrene-butadiene polymerization workers. *Am J Epidemiol.* 1992 Oct 1;136(7):843–54.
28. Delzell E, Sathiakumar N, Hovinga M, Macaluso M, Julian J, Larson R, et al. A follow-up study of synthetic rubber workers. *Toxicology.* 1996 Oct 28;113(1–3):182–9.
29. Macaluso M, Larson R, Delzell E, Sathiakumar N, Hovinga M, Julian J, et al. Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. *Toxicology.* 1996 Oct; 113(1–3):190–202.
30. Delzell E, Macaluso M, Sathiakumar N, Matthews R. Leukemia and exposure to 1,3-butadiene, styrene and dimethylthiocarbamate among workers in the synthetic rubber industry. *Chem Biol Interact.* 2001 Jun;135–136:515–34.
31. Sathiakumar N, Delzell E, Hovinga M, Macaluso M, Julian JA, Larson R, et al. Mortality from cancer and other causes of death among synthetic rubber workers. *Occup Environ Med.* 1998 Apr 1;55(4):230–5.
32. Hsu CD, Momin F, Hess JW, de Carvalho MF. Trends in Cigarette Smoking Prevalence Among Refinery and Petrochemical Plant Workers, 1950 to 1999. *J Occup Environ Med.* 2019 Dec;61(12):989–95.
33. Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol.* 2009 Apr;22(4):734–41.
34. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014 [cited 2024 Jan 25]. (Reports of the Surgeon General). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK179276>.
35. American Cancer Association (ACA). Smoking and Cancer [Internet]. 2020. Available from: <https://www.cdc.gov/tobacco/campaign/tips/diseases/cancer.html>.
36. Thomas X, Chelghoum Y. Cigarette smoking and acute leukemia. *Leuk Lymphoma.* 2004 Jun;45(6):1103–9.
37. Arshad F, Ali A, Rehman G, Halim SA, Waqas M, Khalid A, et al. Comparative Expression Analysis of Breakpoint Cluster Region-Abelson Oncogene in Leukemia Patients. *ACS Omega.* 2023 Feb 14;8(6):5975–82.
38. European Chemicals Agency. Appendix to Chapter R.8, guidance for preparing a scientific report for health-based exposure limits at the workplace: guidance on information requirements and chemical safety assessment. [Internet]. LU: Publications Office; 2019 [cited 2023 Oct 13]. Available from: <https://data.europa.eu/doi/10.2823/333736>
39. National Research Council (NRC). Health Risks of Radon and Other Internally Deposited Alpha-Emitters, Committee on the Biological Effects of Ionizing Radiation, Biological

- Effects of Ionizing Radiation IV (BEIR IV). Washington: National Academy Press Washington DC; 1088.
40. European Commission, Directorate-General for Employment, Social Affairs and Inclusion. Methodology for derivation of occupational exposure limits of chemical agents – The General Decision-Making Framework of the Scientific Committee on Occupational Exposure Limits (SCOEL) 2017. Publications Office, 2018.
41. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. *Am J Hematol.* 2021 Dec;96(12):1679–705.